FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078992128> ?p ?o ?g. }

• W2078992128 endingPage "414" @default.
• W2078992128 startingPage "405" @default.
• W2078992128 abstract "(2 S ,3 R ,4 R ,5 S ,6 R )-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2 H -pyran-3,4,5-triol (dapagliflozin; BMS-512148) is a potent sodium-glucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes. The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological and dispositional behavior in the clinic, involved Caco-2 cell permeability studies, cytochrome P450 (P450) inhibition and induction studies, P450 reaction phenotyping, metabolite identification in hepatocytes, and pharmacokinetics in rats, dogs, and monkeys. Dapagliflozin was found to have good permeability across Caco-2 cell membranes. It was found to be a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor. Dapagliflozin was not found to be an inhibitor or an inducer of human P450 enzymes. The in vitro metabolic profiles of dapagliflozin after incubation with hepatocytes from mice, rats, dogs, monkeys, and humans were qualitatively similar. Rat hepatocyte incubations showed the highest turnover, and dapagliflozin was most stable in human hepatocytes. Prominent in vitro metabolic pathways observed were glucuronidation, hydroxylation, and O -deethylation. Pharmacokinetic parameters for dapagliflozin in preclinical species revealed a compound with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans. The pharmacokinetics in humans after a single dose of 50 mg of [ 14 C]dapagliflozin showed good exposure, low clearance, adequate half-life, and no metabolites with significant pharmacological activity or toxicological concern." @default.
• W2078992128 created "2016-06-24" @default.
• W2078992128 creator A5002921341 @default.
• W2078992128 creator A5022194215 @default.
• W2078992128 creator A5024586439 @default.
• W2078992128 creator A5035374461 @default.
• W2078992128 creator A5035926381 @default.
• W2078992128 creator A5039202929 @default.
• W2078992128 creator A5041366938 @default.
• W2078992128 creator A5044156978 @default.
• W2078992128 creator A5052619784 @default.
• W2078992128 creator A5057871676 @default.
• W2078992128 creator A5065801628 @default.
• W2078992128 creator A5065984250 @default.
• W2078992128 creator A5068080359 @default.
• W2078992128 creator A5087048002 @default.
• W2078992128 date "2009-12-08" @default.
• W2078992128 modified "2023-10-17" @default.
• W2078992128 title "In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans" @default.
• W2078992128 cites W1490154674 @default.
• W2078992128 cites W152943885 @default.
• W2078992128 cites W1967766455 @default.
• W2078992128 cites W1976364114 @default.
• W2078992128 cites W1988586881 @default.
• W2078992128 cites W2000047428 @default.
• W2078992128 cites W2002760082 @default.
• W2078992128 cites W2008846127 @default.
• W2078992128 cites W2014560547 @default.
• W2078992128 cites W2026609170 @default.
• W2078992128 cites W2037254599 @default.
• W2078992128 cites W2045171296 @default.
• W2078992128 cites W2050799458 @default.
• W2078992128 cites W2052321618 @default.
• W2078992128 cites W2067188158 @default.
• W2078992128 cites W2113205708 @default.
• W2078992128 cites W2123355624 @default.
• W2078992128 cites W2142360957 @default.
• W2078992128 cites W2149185387 @default.
• W2078992128 cites W2149973065 @default.
• W2078992128 cites W2150855258 @default.
• W2078992128 cites W2151349499 @default.
• W2078992128 cites W2170364012 @default.
• W2078992128 cites W2171786511 @default.
• W2078992128 cites W2178920245 @default.
• W2078992128 cites W2491374885 @default.
• W2078992128 cites W1978886286 @default.
• W2078992128 doi "https://doi.org/10.1124/dmd.109.029165" @default.
• W2078992128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19996149" @default.
• W2078992128 hasPublicationYear "2009" @default.
• W2078992128 type Work @default.
• W2078992128 sameAs 2078992128 @default.
• W2078992128 citedByCount "145" @default.
• W2078992128 countsByYear W20789921282012 @default.
• W2078992128 countsByYear W20789921282013 @default.
• W2078992128 countsByYear W20789921282014 @default.
• W2078992128 countsByYear W20789921282015 @default.
• W2078992128 countsByYear W20789921282016 @default.
• W2078992128 countsByYear W20789921282017 @default.
• W2078992128 countsByYear W20789921282018 @default.
• W2078992128 countsByYear W20789921282019 @default.
• W2078992128 countsByYear W20789921282020 @default.
• W2078992128 countsByYear W20789921282021 @default.
• W2078992128 countsByYear W20789921282022 @default.
• W2078992128 countsByYear W20789921282023 @default.
• W2078992128 crossrefType "journal-article" @default.
• W2078992128 hasAuthorship W2078992128A5002921341 @default.
• W2078992128 hasAuthorship W2078992128A5022194215 @default.
• W2078992128 hasAuthorship W2078992128A5024586439 @default.
• W2078992128 hasAuthorship W2078992128A5035374461 @default.
• W2078992128 hasAuthorship W2078992128A5035926381 @default.
• W2078992128 hasAuthorship W2078992128A5039202929 @default.
• W2078992128 hasAuthorship W2078992128A5041366938 @default.
• W2078992128 hasAuthorship W2078992128A5044156978 @default.
• W2078992128 hasAuthorship W2078992128A5052619784 @default.
• W2078992128 hasAuthorship W2078992128A5057871676 @default.
• W2078992128 hasAuthorship W2078992128A5065801628 @default.
• W2078992128 hasAuthorship W2078992128A5065984250 @default.
• W2078992128 hasAuthorship W2078992128A5068080359 @default.
• W2078992128 hasAuthorship W2078992128A5087048002 @default.
• W2078992128 hasConcept C112705442 @default.
• W2078992128 hasConcept C134018914 @default.
• W2078992128 hasConcept C150903083 @default.
• W2078992128 hasConcept C178790620 @default.
• W2078992128 hasConcept C185592680 @default.
• W2078992128 hasConcept C188053792 @default.
• W2078992128 hasConcept C202751555 @default.
• W2078992128 hasConcept C207001950 @default.
• W2078992128 hasConcept C2776980637 @default.
• W2078992128 hasConcept C2777180221 @default.
• W2078992128 hasConcept C2777422806 @default.
• W2078992128 hasConcept C537181965 @default.
• W2078992128 hasConcept C55493867 @default.
• W2078992128 hasConcept C555293320 @default.
• W2078992128 hasConcept C71924100 @default.
• W2078992128 hasConcept C86803240 @default.
• W2078992128 hasConcept C98274493 @default.
• W2078992128 hasConceptScore W2078992128C112705442 @default.
• W2078992128 hasConceptScore W2078992128C134018914 @default.

• next